Severe chronic rhinosinusitis with nasal polyps
Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
Initiation Criteria - Add on to standard of care for adult patients (18 and plus) with severe nasal polyps inadequately controlled by intranasal corticosteroids (INCS) alone defined as: Documented diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) through either CT or endoscopy; and Symptoms persisting for at least 8-12 weeks despite treatment with INCS Administration Criteria - Patient must be managed by a physician experienced in the treatment of CRSwNP (allergist, ENT, respirologist) - Prior to initiating Nucala, baseline assessment of patient reported symptoms and/or quality of life (i.e. SNOT-22 or VAS) Renewal Criteria - Clinical response should be assessed after 1 year Improvement in patient reported symptoms based on baseline assessment (i.e. SNOT-22, VAS) if in the first year of treatment, or maintenance of this improvement if in subsequent years of treatment
Nucala is indicated as add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.